Eating cancer

How HDAC inhibitors turn immunosuppressive macrophages against tumors

With immuno-oncology companies increasingly looking beyond T cells to other immune cell types that could drive an antitumor response, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has hit on a new strategy for enlisting macrophages. Although the cells are often viewed as bad actors in cancer, shielding tumors from an immune attack, the company has shown that epigenetics can be used to convert macrophages from a protumor to

Read the full 655 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE